The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...

The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...

Prime Minister Narendra Modi on Friday asked scientists and entrepreneurs to focus more on research and development (R&D), ...

Akums reports Q1 FY26 total income of Rs. 1,051 crore with 2.4% growth, 19% YoY adjusted EBITDA growth: Our Bureau, Bengaluru Tuesday, August 12, 2025, 15:30 Hrs [IST] Akums Drugs ...

Pharmexcil and Mexican Consulate join hands to chart new avenues for Indian pharma expansion: Shardul Nautiyal, Mumbai Tuesday, August 12, 2025, 08:00 Hrs [IST] In a bid to unlock ...

Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.

The new label for Forxiga/Farxiga (dapagliflozin) comes from the DECLARE-TIMI 58 trial, and the EU is the first major market to approve the label update, ahead of the US and China where it remains ...

The risk of new-onset diabetic retinopathy (DR) increased slightly, but significantly, in patients taking GLP-1 receptor ...

Q: I have Type 2 diabetes, and my doctor insists that I give up beverages with almost all sugar substitutes and stick with water. Can you explain what’s wrong with ...

In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...

Researchers from Thomas Jefferson University have discovered that combining two diabetes drugs—dapagliflozin and ...